| Recruiting | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic NCT06998940 | SWOG Cancer Research Network | Phase 3 |
| Recruiting | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenoc NCT07214298 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma NCT07089940 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Recruiting | BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and R NCT07226856 | Mayo Clinic | Phase 2 |
| Withdrawn | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Col NCT06626256 | City of Hope Medical Center | Phase 1 |
| Recruiting | TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, NCT07189195 | University of California, Davis | Phase 1 |
| Withdrawn | FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma NCT06206876 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced NCT06906562 | Sameek Roychowdhury | Phase 2 |
| Recruiting | Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NCT06958328 | NRG Oncology | Phase 3 |
| Active Not Recruiting | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Brea NCT06630325 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally A NCT06381154 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Assoc NCT06115499 | Alliance for Clinical Trials in Oncology | Phase 2 / Phase 3 |
| Withdrawn | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-adva NCT06398587 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, NCT05911243 | University of Washington | N/A |
| Recruiting | Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer NCT06454383 | City of Hope Medical Center | Phase 1 |
| Recruiting | Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis NCT04858009 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial NCT05554367 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia NCT06073431 | University of Rochester | — |
| Terminated | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreat NCT04975516 | Mayo Clinic | Phase 2 |
| Recruiting | CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer NCT05685602 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati NCT05733000 | Northwestern University | Phase 2 |
| Withdrawn | SMMART Adaptive Clinical Treatment (ACT) Trial NCT05238831 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Recruiting | Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors NCT05053971 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer NCT05034627 | OHSU Knight Cancer Institute | Phase 1 |
| Terminated | Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma NCT04809766 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer NCT04821284 | Flemming Forsberg | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumor NCT04514497 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fa NCT04673448 | University of Washington | Phase 1 |
| Recruiting | Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer NCT04158635 | City of Hope Medical Center | Phase 1 |
| Recruiting | Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancre NCT04887805 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Trea NCT04616534 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events NCT05038254 | M.D. Anderson Cancer Center | N/A |
| Terminated | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma NCT04387071 | University of Southern California | Phase 1 / Phase 2 |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients NCT04548752 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Com NCT04837118 | M.D. Anderson Cancer Center | N/A |
| Recruiting | iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation NCT03608631 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancre NCT04493060 | Mayo Clinic | Phase 2 |
| Terminated | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutat NCT04390243 | Academic and Community Cancer Research United | Phase 2 |
| Withdrawn | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumor NCT03925428 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic NCT04524702 | Emory University | Phase 2 |
| Active Not Recruiting | Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Lipo NCT04233866 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Recruiting | Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pan NCT04115163 | Anne Noonan | Phase 2 |
| Completed | Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study NCT04449679 | Thomas Jefferson University | N/A |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Withdrawn | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer NCT04058964 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer NCT04191421 | Emory University | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine NCT03816358 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer NCT04132505 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreat NCT04050085 | University of California, Davis | Phase 1 |
| Recruiting | Targeted Pathway Inhibition in Patients With Pancreatic Cancer NCT04005690 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Withdrawn | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer NCT03432676 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors NCT03784677 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer NCT04067960 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer NCT03910387 | Emory University | Phase 2 |
| Recruiting | Intravital Microscopy in Human Solid Tumors NCT03823144 | Mayo Clinic | N/A |
| Terminated | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer NCT03723915 | Northwestern University | Phase 2 |
| Completed | IACS-010759 in Advanced Cancers NCT03291938 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors o NCT03033225 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung C NCT02983578 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Rem NCT02595931 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer NCT02671890 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With NCT01585805 | National Cancer Institute (NCI) | Phase 2 |